Sign in
Stories
Breakthrough Antibody for Leukemia Treatment
Share
ACTICOR BIOTECH Delays Key Documents
Advancements in Cancer Treatment and Mar...
AnaMar Receives Orphan Drug Designation ...
ANJESO Drug Insight and Market Forecast
Advancing OSE-279: Promising Cancer Trea...
Aligos Therapeutics Financial Disclosure
Overview
API
Immune-Onc Therapeutics secures FDA Orphan Drug Designation for IO-202, a promising antibody for treating Chronic Myelomonocytic Leukemia (CMML). The company is advancing Phase 1 trials in partnership with azacitidine.
Ask a question
How does Orphan Drug Designation impact the development and accessibility of novel therapies?
In what ways could the success of IO-202 in CMML treatment influence research in other cancer types or medical fields?
What challenges might Immune-Onc Therapeutics face in advancing IO-202 through clinical trials and regulatory approvals?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage